Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms TOPARP
- 07 Jun 2017 Biomarkers information updated
- 18 Feb 2017 Results of exploratory analysis presented at the 2017 Genitourinary Cancers Symposium
- 28 Jan 2016 According to an AstraZeneca media release, olaparib [Lynparza] has been granted breakthrough therapy designation by the US FDA for the monotherapy treatment of BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide). The breakthrough therapy designation was based on the results of this trial.